

Exploring pitfalls of ^{64}Cu -labeled EGFR-targeting peptide GE11 as a potential PET tracer

Striese, F.; Sihver, W.; Gao, F.; Bergmann, R.; Walther, M.; Pietzsch, J.; Steinbach, J.;
Pietzsch, H.-J.;

Originally published:

July 2018

Amino Acids 50(2018)10, 1415-1431

DOI: <https://doi.org/10.1007/s00726-018-2616-5>

Perma-Link to Publication Repository of HZDR:

<https://www.hzdr.de/publications/Publ-27783>

Release of the secondary publication
on the basis of the German Copyright Law § 38 Section 4.

[Click here to view linked References](#)

Exploring pitfalls of ^{64}Cu -labeled EGFR targeting peptide GE11 as a potential PET tracer

1
2 **Franziska Striese^{1,2}, Wiebke Sihver^{1,*}, Feng Gao¹, Ralf Bergmann¹, Martin Walther¹, Jens**
3 **Pietzsch^{1,2}, Jörg Steinbach^{1,2}, Hans-Jürgen Pietzsch¹**
4
5
6

7 ¹ *Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400,*
8 *01328 Dresden, Germany;*
9

10 ² *Technische Universität Dresden, Department of Chemistry and Food Chemistry, 01062 Dresden, Germany*
11
12
13
14
15

16 **Abbreviated title:** ^{64}Cu -labeled EGFR peptides for cancer imaging
17
18
19

20 **Key words:** epidermal growth factor receptor, ^{64}Cu -labeled peptide conjugates, molecular imaging,
21 receptor tyrosine kinases, positron emission tomography
22
23
24
25
26

27 ***Corresponding author:** w.sihver@hzdr.de
28

29 Tel.: +49-351-260-2424
30

31 Fax: +49-351-260-3232
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **Acknowledgments**

49

50 The authors thank Uta Herzog, Regina Herrlich and Andrea Suhr for their excellent technical assistance. The authors
51 further wish to thank Frank Starke, Ph.D., for the synthesis and characterization of the GE11 conjugates as well as the
52 colleagues operating at the cyclotron, Ulrike Gesche and Stefan Preusche, and the staff of the Production of
53 Radiopharmaceuticals Department at the Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum
54 Dresden-Rossendorf for the production of ^{64}Cu . F.G. thanks the German Academic Exchange Service (DAAD) for
55 financial support (A/11/94299, 91540213). The authors also thank Ian Moore Gilpin for proofreading.
56
57
58
59
60
61
62
63
64
65

Abstract

1 The epidermal growth factor receptor (EGFR) represents an important molecular target for both radiotracer-based
2 diagnostic imaging and radionuclide therapy of various cancer entities. For the delivery of radionuclides to the tumor,
3 peptides hold great potential as a transport vehicle. With respect to EGFR, the peptide YHWYGYTPQNVI (GE11) has
4 been reported to bind the receptor with high specificity and affinity. In the present study, GE11 with β -alanine (β -Ala-
5 GE11) was conjugated to the chelating agent *p*-SCN-Bn-NOTA and radiolabeled with ^{64}Cu for the first
6 radiopharmacological evaluation as a potential probe for positron emission tomography (PET)-based cancer imaging. For
7 better water solubility, an ethylene glycol-based linker was introduced between the peptide's N-terminus and the
8 radionuclide chelator. The stability of the ^{64}Cu -labeled peptide conjugate and its binding to EGFR-expressing tumor cells
9 was investigated in vitro and in vivo, and then compared with the ^{64}Cu -labeled EGFR-targeting antibody conjugate
10 NOTA-cetuximab. The GE11 peptide conjugate [^{64}Cu]Cu-NOTA-linker- β -Ala-GE11 ([^{64}Cu]Cu-**1**) was stable in a buffer
11 solution for at least 24 h but only 50% of the original compound was detected after 24 h of incubation in human serum.
12 Stability could be improved by amidation of the peptide's C-terminus (β -Ala-GE11-NH₂ (**2**)). Binding assays with both
13 conjugates, [^{64}Cu]Cu-**1** and [^{64}Cu]Cu-**2**, using the EGFR-expressing tumor cell lines A431 and FaDu showed no specific
14 binding. A pilot small animal PET investigation in FaDu tumor bearing mice revealed only low tumor uptake (standard
15 uptake value (SUV) < 0.2) for both conjugates. The best tumor-to-muscle ratio determined was 3.75 for [^{64}Cu]Cu-**1**, at 1
16 h post injection. In conclusion, the GE11 conjugates in its present form are not suitable for further biological
17 investigations, since they presumably form aggregates.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction

1 The epidermal growth factor receptor (EGFR) is a transmembrane located receptor tyrosine kinase that regulates
2 proliferation, differentiation or survival of cells (Wee and Wang, 2017). However, improper receptor activation may lead
3 to a malignant cell transformation and drives cancer progression and pathogenesis. Deregulation of the receptor activity
4 in cancer cells is mostly the consequence of activating mutations or protein overexpression (Mendelsohn and Baselga
5 2006). The latter has been reported for various epithelial cancers, such as head and neck, breast, prostate, bladder,
6 colorectal, non-small cell lung cancer and glioma (Salomon et al. 1995). Moreover, EGFR overexpression often correlates
7 with lowered overall survival and increased cancer recurrence (Selvaggi et al. 2001; Nicholson et al. 2001; Tsutsui et al.
8 2002). Therefore, the receptor has become an important molecular target for anticancer therapy and imaging (Sihver et
9 al. 2014; Koi et al. 2014). Radionuclide-based molecular imaging, such as positron emission tomography (PET) can
10 provide accurate, non-invasive and repetitive visualization of EGFR-overexpression on tumors and metastases. Moreover,
11 it can be used for more applications, like monitor treatment responses and as a prognostic indicator for EGFR expressing
12 tumors. For this purpose, many selective EGFR targeting ligands, from small molecular inhibitors to EGF-derived and
13 antibody-based ligands, have been labeled with different radionuclides (Sihver et al. 2014; Yoshimoto et al. 2015; van
14 Dijk et al. 2015)).

15 So far, there are few reported studies that have been conducted to image the EGFR, although more are presumably in
16 progress (Petrulli et al. 2017; van Loon et al. 2017; Lindenberg et al. 2017). They show high accumulation in the liver
17 with an unfavorable ratio compared to tumor accumulation. As an alternative targeting vector, peptides may be used. In
18 the recent years, peptides became interesting radiotracers for cancer imaging since they might combine high target affinity
19 with small molecule size, thus resulting in more favorable pharmacokinetics than antibodies. Furthermore, they are often
20 less immunogenic (Chen and Chen 2010). Radioactive metabolites are renally eliminated relatively fast, *via* the kidneys
21 (Bröer 2008) and, depending on the structure, not trapped in the liver. However, accumulation in the kidneys has to be
22 monitored carefully, since they are often the dose-limiting organ for studies with radiolabeled substances. Moreover,
23 peptides seem to be advantageous over complex proteins as they tolerate harsher conditions for radionuclide labeling (pH,
24 temperature) and can be synthesized and manipulated more easily (Signore et al. 2001; Reubi and Maecke 2008). Because
25 of these advantages, a number of peptide-based radiotracers have already been successfully developed for the imaging of
26 tumors, e.g. ⁶⁸Ga-labeled octreotide (GaTate) targeting the somatotatin receptor as a marker of neuroendocrine tumors
27 (Hofman et al. 2012).

28 Li et al., (2005) developed an EGFR-specific peptide with a 12-amino acid sequence (YHWYGYTPQNVI), by screening
29 a phage display library with human EGFR (hEGFR). This peptide named GE11 was radioiodinated with ¹²⁵I at its tyrosine
30 residues. This labeling technology potentially resulted in a mixture of three different molecules that could not be purified.
31 The saturation binding assay showed for this mixture of ¹²⁵I-labeled GE11 peptides a moderate affinity of 22 nM which
32 was determined in EGFR overexpressing cancer cells. Additionally, it has been shown that GE11 internalizes in such
33 cells, and it can accumulate specifically in human hepatoma xenografted mice. Binding of the peptide could be displaced
34 by EGF showing that it is specific for the EGFR. However, even though it binds into the EGF binding pocket, GE11 had
35 only low mitogenic activity (Li et al. 2005).

36 Potential applications of GE11 comprises of conjugates with other larger molecules like nanoparticles, liposomes,
37 micelles and/or with polymer compounds such as polyethylene glycol (PEG) and polyethylenimine (PEI) for the therapy
38 of EGFR overexpressing tumors (Master et al. 2013; Cheng et al. 2014; Tang et al. 2014; Ren et al. 2015; Chanda et al.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2010; Zarschler et al. 2014; Genta et al. 2018). Radiolabeled GE11 conjugates have been already prepared with the intention of diagnostic imaging (Dissoki et al. 2011; DeJesus 2012; Yu et al. 2015; Rahmanian et al. 2017).

In the present study, approached as a proof-of-concept investigation, the GE11 peptide was conjugated through β -alanine with the chelator 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) at the peptides' N-terminus. The β -Alanine is commonly used as a spacer due to its chemical versatility for covalent conjugation (Banerjee et al. 2012). This amino acid does not have to be protected in the peptide synthesis, it prevents racemization and is useful for enantioselective synthesis (Kondo et al. 1987; Gutiérrez-García et al. 2001). Additionally, an ethylene glycol (EG)-based linker was introduced to enhance the solubility in aqueous buffer. This approach should result in a chemically and stereochemically pure compound. After ^{64}Cu -labeling, radiopharmacological investigations of the peptide conjugates were performed with regard to cell binding in vitro, as well as biodistribution and accumulation in tumors from the head and neck squamous cell carcinoma (HNSCC) cell line FaDu in xenografted mice in vivo. The focus of the project was to develop a diagnostic imaging tool, particularly for HNSCC, since elevated EGFR expression in such entities have been associated with poor clinical prognosis and resistance to chemotherapy and radiation therapy (Ang et al. 2002; Baumann and Krause 2004; Martínez-Useros and García-Foncillas 2015). Hence, the moderately high EGFR expressing HNSCC cell line FaDu was used, especially for xenografting. Thus, the potential of the peptide conjugates as candidates for further application as diagnostic PET tracers was intended to be estimated and finally compared with the EGFR-targeting antibody conjugate, ^{64}Cu -radiolabeled NOTA-cetuximab.

Materials and Methods

Chemicals and equipment

Chemical reagents and solvents were purchased from commercial sources, without further purification. *p*-SCN-Bn-NOTA was purchased from Macrocyclics (Dallas, TX, USA), LiChrolut[®]RP-18 cartridges from Merck Millipore Group (Darmstadt, Germany) and Jumbo- or Macrosep centrifugal devices with a molecular weight cut-off (MWCO) of 30 kDa were received from Pall Corporation (Ann Arbor, MI, USA). The EG-based linker (cf. Fig. 1) was prepared in-house (Heldt et al. 2013).

β -Alanine-YHWYGYTPQNVI (β -Ala-GE11) and β -Alanine-YHWYGYTPQNVI-NH₂ (β -Ala-GE11-NH₂) were purchased from GL Biochem (Shanghai, China). Cetuximab (Erbix[®], C225) was purchased from Merck Serono (Darmstadt, Germany).

HPLC was carried out with an HPLC system of Knauer (Berlin, Germany), equipped with a Smartline 2800 UV/Vis-detector and, for radiochemical analysis, a flow-through radioactivity detector Ramona from Raytest GmbH (Straubenhardt, Germany). Knauer Eurospher 100 C18 columns (5 μm , X \times 250 mm) with an inner diameter of either 4 mm or 8 mm were used for analysis or purification of the GE11 peptide conjugates, respectively. For these columns the mobile phase consists of water (**A**) and acetonitrile (AcN) + 0.1% trifluoroacetic acid (TFA) (**B**); the flow was 1 mL/min. A YMC-BioPro QA-F column (5 μm , 4.6 \times 100 mm) was used for analytical HPLC of NOTA₃-C225. Here, the mobile phase was composed of 20 mM Tris/HCl (pH 8.5) (**A**) and 1 M NaCl in 20 mM Tris/HCl (pH 8.5) (**B**) with a 0.35 mL/min flow.

Matrix-assisted-laser desorption/ionization – time of flights mass spectrometry (MALDI-TOF-MS) was carried out with a *Daltonic Autoflex II* TOF/TOF mass spectrometer from Bruker Daltonics (Bremen, Germany) and 0.1 M sinapinic acid

(3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoic acid) as a matrix, which was dissolved in a mixture of AcN, ddH₂O (60/40 (v/v)) and 0.1% TFA.

The ⁶⁴Cu (*t*_{1/2} = 12.7 h) production was performed at the Helmholtz-Zentrum Dresden-Rossendorf with a Cyclone 18/9 cyclotron (IBA, Louvain la Neuve, Belgium) via the ⁶⁴Ni(p,n)⁶⁴Cu reaction. Radioactive samples were counted using a 1480 WIZARD 3'' automatic gamma counter from PerkinElmer (Waltham, USA).

Cell culture reagents were obtained from Biochrom GmbH (Berlin, Germany).

Synthesis of GE11 and C225 conjugates

β-Ala-GE11 and β-Ala-GE11-NH₂. Both peptides comprised an additional β-alanine at the N-terminus for conjugation reactions (Fig. 1A).

NOTA-β-Ala-GE11. β-Ala-GE11 (5.58 μmol) and triethylamine (TEA, 55.8 μmol) were dissolved in anhydrous dimethylformamide (DMF). A solution of *p*-SCN-Bn-NOTA (5.58 μmol) in anhydrous DMF (700 μL) was added and the reaction mixture shaken over night (o/n) at room temperature (RT). The pale yellow solution was finally purified by HPLC (gradient from A: 75% to 64% in 20 min: retention time (*t*_R)= 12.9 min) and the product freeze-dried obtaining a white solid with a chemical yield of 37%. MALDI-TOF *m/z*: 2062.9 [M+H]⁺ (expected mass: 2062.3).

linker-β-Ala-GE11, linker-β-Ala-GE11-NH₂. The EG-based linker precursor (8 μmol) and the coupling reagent CoMu (8 μmol) were dissolved in anhydrous DMF (500 μL). β-Ala-GE11 or β-Ala-GE11-NH₂ (8 μmol), and diisopropylethylamine (80 μmol) in anhydrous DMF (500 μL) were added to the linker precursor. The reaction mixture was shaken o/n at RT. After addition of piperidine (2 mL) and anhydrous DMF (1 mL), the reaction mixture was stirred for 1 h at 40 °C. The solvents were removed on a rotary evaporator and the residual yellowish oil purified by HPLC (gradient from A: 80% to 67% in 25 min: linker-GE11 *t*_R= 18.7 min, linker-GE11-NH₂ *t*_R= 21.1 min). After freeze-drying, both peptides were obtained as white solids with chemical yields of 38% and 53%, respectively. MALDI-TOF *m/z*: 1861.5 [M+2H]⁺ (expected mass: 1858) (linker-β-Ala-GE11), MALDI-TOF *m/z*: 1858 [M+H]⁺ (expected mass: 1857) (linker-β-Ala-GE11-NH₂).

NOTA-linker-β-Ala-GE11 (=1), NOTA-linker-β-Ala-GE11-NH₂ (=2). (Fig. 1B) linker-β-Ala-GE11, or linker-β-Ala-GE11-NH₂ (1 μmol), and TEA (1 μmol) were dissolved in anhydrous DMF (300 μL). A solution of *p*-SCN-Bn-NOTA (1 μmol) in anhydrous DMF (300 μL) was added and the reaction mixture shaken o/n at RT. The pale yellow solution was purified by HPLC (gradient from A: 80% to 60% in 30 min: **1** *t*_R= 20.5 min, **2** *t*_R= 21.2 min). After freeze-drying, **1** and **2** were obtained as white solids with chemical yields of 62% and 63%, respectively. MALDI-TOF *m/z*: 2308.1 [M+H]⁺ (expected mass: 2307) (**1**), 2309.2 [M+H]⁺ (expected mass: 2308) (**2**).

NOTA₃-C225. The C225 solution (8 mL, 5 mg/mL, 40 mg, 263.2 nmol) was buffer exchanged using centrifugal filter units with a 30 kDa MWCO for a NaHCO₃ buffer (55 mL, 50 mM containing 0.9% NaCl, pH 6.4) and concentrated to a final volume of 3.5 mL. *p*-SCN-Bn-NOTA (27.3 mg, 49 μmol) was dissolved in a HEPES buffer (0.5 M, 2 mL, pH 7.2) and added dropwise to the buffer-exchanged C225 solution, which was then filled up to 6.89 mL with the HEPES buffer (molar ratio *p*-SCN-Bn-NOTA:C225 185:1) obtaining pH 6.9. After 22 h at RT, the modified C225 solution was purified from unbound *p*-SCN-Bn-NOTA, again using centrifugal filter units with a 30 kDa MWCO and a NaHCO₃ buffer (55 mL, 50 mM containing 0.9% NaCl, pH 6.4) and concentrated to a final volume of 1 mL. The yield of NOTA₃-C225 was determined by UV/Vis spectroscopy at 280 nm, resulting in 260 nmol (99%). HPLC (gradient from A: 100% to 0% in 20

min: $t_R = 5.1$ min). The identification of the final product and the number of coupled NOTA chelator molecules was confirmed by MALDI-TOF (m/z : 154106.6 $[M+H]^+$) (Schubert et al. 2017).

A -NH-Tyr-His-Trp-Tyr-Gly-Tyr-Thr-Pro-Gln-Asn-Val-Ile-OH (GE11)
 -NH-Tyr-His-Trp-Tyr-Gly-Tyr-Thr-Pro-Gln-Asn-Val-Ile-NH₂ (GE11-NH₂)




Fig. 1 (A) Amino acid sequences of GE11 and GE11-NH₂, (B) [⁶⁴Cu]Cu-1 and [⁶⁴Cu]Cu-2

Radiolabeling of the peptide conjugates and NOTA₃-C225

The ⁶⁴Cu-labeling of the **1** or **2** conjugate was conducted as follows: 2-(N-morpholino) ethanesulfonic acid (MES) buffer (0.2 M, 100 μ L, pH 6.2) was mixed with the peptide conjugate (until 10 μ M). Thereafter, up to 50 MBq [⁶⁴Cu]CuCl₂/0.01 M HCl were added to the peptide conjugate-MES solution. The reaction was supplemented with water to a final volume of 400 μ L. After shaking the reaction vial (polypropylene vials, Eppendorf) for 1 h at 50 °C, the radiochemical purity was monitored by HPLC (gradient from **A**: 90% to 10% in 20 min).

(⁶⁴Cu]Cu-NOTA)₃-C225 was prepared by first buffering the [⁶⁴Cu]CuCl₂/0.01 M HCl (50 to 80 MBq) solution with one equivalent volume of a MES-buffer (1 M, pH 6.0). Then, NOTA₃-C225 (0.5 nmol) was added to a MES-buffer (0.1 M, pH 6.0). Both solutions were mixed and incubated for 45 min at 30 °C. Then, a 6-fold molar excess of ethylenediaminetetraacetic acid (EDTA) was added and incubated for a further 15 min at RT. The radiochemical purity was determined by radio-instant thin layer chromatography (iTLC) using iTLC-SA plates (Agilent Technologies, Santa Clara, CA, USA) and water as the mobile phase. The Rita-Star image reader (Raytest GmbH, Germany) was used for the analysis of the plates.

Octanol/buffer partition coefficient (LogD). 20 μ L of [⁶⁴Cu]Cu-**1** or [⁶⁴Cu]Cu-**2** (0.2 MBq) was diluted into 500 μ L of PBS. 500 μ L of n-octanol was added and the mixture stirred for 30 min at RT. Subsequently, the mixture was centrifuged for 30 min (14,000g) at RT; 450 μ L of both water and n-octanol phases were taken and centrifuged again. The activity of 100 μ L of both the buffer phase and the octanol phase was measured in a gamma counter and the LogD was calculated. The experiments were performed three times.

In vitro characterization

Stability in human serum, cell medium and MES-buffer. The integrity of the ⁶⁴Cu-labeled peptide conjugates was evaluated for the following media: human serum, cell culture medium DMEM + 10% fetal calf serum (FCS) (with (w/) and without (w/o) the presence of A431 cells) and 0.2 M MES-buffer pH 6.2. The incubation took 2 h and 24 h at 37 °C,

1 respectively. Conjugate degradation was monitored by analytical HPLC. Before HPLC analysis, the conjugates were
2 extracted from the biological fluid with a LiChrolut® RP18 cartridge. The peptides were eluted from the cartridge with
3 AcN/ddH₂O (80/20 (v/v)), which was subsequently evaporated to dryness. Then, the conjugate peptides were dissolved
4 in a MES-buffer (100 µL, 0.2 M, pH 6.2) and applied to the HPLC column (gradient from A (water): 90% to 10% in 20
5 min, (B: AcN + 0.1% TFA)). A small part of [⁶⁴Cu]Cu-1 and [⁶⁴Cu]Cu-2 was kept for MALDI-TOF-MS analysis. The
6 HPLC radioflow-peak areas were measured by employing manual peak integration. The remaining portion of the parent
7 compound was calculated by determining the area of the parent radioflow-peak as a percentage of the total area of all
8 peaks. For mass determination, the solution was again evaporated. The measurements resulted in *m/z*: 2370.2 [M+H]⁺
9 (parental peptide Cu-1, expected mass 2369), 2369.3 [M+H]⁺ (parental peptide Cu-2, expected mass 2368); for both
10 peptides 1899.7 [M+H]⁺ (Cu-NOTA-linker-β-Ala-Tyr-His-Trp-Tyr-Gly-Tyr-Thr-Pro, expected mass 1899), 1542.5
11 [M+H]⁺ (Cu-NOTA-linker-β-Ala-Tyr-His-Trp-Tyr-Gly, expected mass 1539). The experiment was repeated at least twice
12 for each peptide conjugate.
13
14
15
16

17 *Cell assays*

18
19 The cell culture assays were assessed using the highly EGFR expressing human epidermoid carcinoma cell line A431
20 (2.6 Mio EGFR/cell; Haigler et al. 1978) (ATCC® CRL-1555), the moderately highly EGFR expressing HNSCC cell line
21 FaDu (0.24 Mio EGFR/ cell; Schütze et al 2007) (ATCC® HTB-43) and, as a control, the non-EGFR expressing human
22 melanoma cell line MDA-MB435s (ATCC® HTB-129). The cells were grown as a monolayer up to confluence at 37 °C
23 in a humidified atmosphere comprising of 5% CO₂ in a DMEM medium supplemented with 10% FCS.
24
25
26

27
28 *Verification of EGFR protein levels for A431, FaDu and MDA-MB-435s cells.* Whole cell lysates were prepared and the
29 protein concentration of each sample was determined by the bicinchoninic acid (BCA) protein assay kit (see below).
30 Equal amounts of denatured protein (3 µg) were separated by SDS-PAGE (with 10% separating gel) and subsequently
31 transferred onto a polyvinylidene fluoride (PVDF) membrane. The membrane was blocked with 5% bovine serum
32 albumin (BSA) in Tris-buffered saline + 0.1% Tween® 20 (TBST) for 1 h, followed by a 1 h-incubation with appropriate
33 primary antibodies (rabbit anti-EGFR 1:10000; rabbit anti-β-actin 1:5000, New England Biolabs; Frankfurt am Main,
34 Germany) diluted with 5% BSA in TBST. After washing three times in TBST, the blots were incubated with a horseradish
35 peroxidase (HRP)-conjugated secondary antibody (goat anti-rabbit-HRP 1:40000, New England Biolabs) for 1 h in 5%
36 BSA-TBST. The visualization of the HRP-enzyme activity was accomplished with Western blotting luminol reagent
37 according to manufacturer's instructions (Santa Cruz Biotechnology, Dallas, TX, USA). Enhanced chemiluminescence
38 was detected with an imaging system suitable for chemiluminescent Western blots (Stella 2000, Raytest).
39
40
41
42
43
44

45
46 *Viability assay.* Standard MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-
47 tetrazolium)-assay (CellTiter 96® Aqueous One Solution Cell Proliferation Assay, Promega, Madison, WI, USA) was
48 performed in order to study the growth influence of β-Ala-GE11 (1.3 µM to 130 µM) in comparison with C225 (0.7 nM
49 to 330 nM) in A431 and FaDu cells. The method was performed according to the manufacturer's protocol. Absorption at
50 a wavelength of 492 nm was recorded by Sunrise™ microplate reader (Tecan Group, Männedorf, Switzerland). As control
51 for viability termination cell samples were treated with 0.1% of Triton X-100.
52
53

54
55 *Saturation binding assays on cell homogenate.* To avoid ligand-receptor internalization, cell homogenate was prepared.
56 After detaching from the culture dish, cells were centrifuged for 5 min at 600g and the pellets subsequently stored at -80
57 °C until usage. For an assay, pellets were thawed in medium and homogenized with a homogenizer (Potter-Elvehjem) by
58 20 strokes on ice.
59
60
61
62
63
64
65

1 For saturation assays, cell homogenate was exposed to varying concentrations of [⁶⁴Cu]Cu-1/2 (0.4 to 50 nM, molar
2 activities of 5 to 10 GBq/μmol) and for comparison with the standard EGFR ligand ([⁶⁴Cu](Cu-NOTA)₃-C225 (0.2 to 20
3 nM, molar activities of 50 to 100 GBq/μmol) for 1 h at 4 °C and 37 °C, respectively. Adjacent samples additionally
4 received 50 μM β-Ala-GE11, β-Ala-GE11-NH₂ or 0.33 μM C225 to assess the nonspecific binding. The incubation was
5 terminated by filtration through GF/C Whatman filters (treated with 0.3% PEI for at least 90 min) using a harvester
6 (Brandel, Glasgow, UK). After washing the filters four times with ice-cold phosphate buffered saline (PBS), they were
7 punch-transferred into vials and counted in a gamma counter. To determine adhered activity to the incubation vials, the
8 PBS washed vials also were measured in the gamma counter.

9
10
11 *Saturation binding and displacement assays in intact cells.* Cells were seeded at a density of 1.5×10^5 cells/well (48-well
12 plates). After 24 h for attaching, the cells were washed twice with 500 μL PBS. To reduce the nonspecific binding at the
13 plastic device, the culture dishes were blocked with 500 μL of 10 g/L BSA in PBS for 1 h. Then, incubation with the
14 radioligand and determination of nonspecific binding was performed as describe above for the homogenate procedure.
15 For competition studies, A431 cells first received up to 1 mM of either β-Ala-GE11 or β-Ala-GE11-NH₂, up to 1 μM of
16 EGF or up to 0.33 μM of C225 at 4 °C and 37 °C for 1 h. Then, ([⁶⁴Cu](Cu-NOTA)₃-C225 (1 nM) was added for another
17 hour. The incubation was terminated by aspirating the binding medium, after which the cells were rinsed thrice with ice-
18 cold PBS to remove any unbound radioligand. Finally, the cell monolayer was dissolved by incubating them with 1 mL
19 cell lysis buffer (0.1 M NaOH and 1% SDS) for 30 min at RT. 500 μL of the cell lysate were used to quantify the activity
20 of cell-bound ligand in the gamma counter. To measure radioligand binding only to the plastic device, an identical
21 saturation binding assay was conducted without cells.

22
23
24
25
26
27
28 The protein concentration of cell samples (homogenate and intact cell assay) was determined by the BCA protein assay
29 kit (Pierce™ Thermo Scientific; Waltham, MA, USA) according to manufactures' instruction measuring the absorbance
30 of the protein color complex at 562 nm with a spectrophotometer (Multimode Reader Varioscan™Flash, Thermo
31 Scientific) in comparison to a BSA standard curve.

32
33
34
35 The binding data were calculated by performing nonlinear curve fitting with GraphPad Prism 5.03.

36
37 *EGF-displacement using immunoblotting analysis.* The assay was performed to find out in a different way, whether GE11,
38 as compared to C225, can be displaced by EGF and thus prevent the phosphorylation of the EGFR. 5000 A431 cells/well
39 were seeded into a flat bottom 12-well plate. After 48 h, the medium was replaced by DMEM (500 μL) and incubated for
40 further 24 h in the incubator. Then, the serum-starved cells were treated with or without 0.1 and 1 mg/mL β-Ala-GE11,
41 10 and 100 μg/mL C225 or vehicle controls for 4 h at 37 °C. Thereafter, the cells were stimulated with 0.1 μg/mL of EGF
42 for 15 min or left unstimulated. Following, cell lysis, sample preparation, SDS-PAGE and Western blotting were
43 conducted equivalent to the procedures in the section: *Verification of EGFR protein levels*. Then, an immunostaining was
44 performed with rabbit anti-phosphorylated-EGFR(Y1173) (1:2500, New England Biolabs) diluted in 5% BSA in TBST
45 or rabbit anti-β-actin as primary antibodies and goat anti-rabbit-HRP as secondary antibody. After detection, the primary
46 and secondary antibodies were removed from the PVDF membrane by stripping (0.1 M NaOH, 0.5% dithiothreitol, 2%
47 SDS) for 15 min at 55 °C. The membrane was subsequently washed twice with TBS for 5 min and a second
48 immunostaining was conducted as described in *Verification of EGFR protein levels* with rabbit anti-EGFR and rabbit
49 anti-β-actin as primary antibodies and goat anti-rabbit-HRP as secondary antibody.

Animal experiments

1 Male Wistar rats (aged 5 to 6 weeks, 200 ± 11 g; Harlan Winkelmann GmbH, Borchon, Germany) and female NMRI
2 *nu/nu* mice (aged about 11 weeks; Experimental Centre of the Medical Faculty Carl Gustav Carus, Technische
3 Universität, Dresden, Germany) were kept under standard conditions with free access to food and water. For blood
4 drawing venous catheters were placed.
5

6
7 To establish the FaDu xenograft model small pieces from source tumors of human hypopharyngeal carcinoma FaDu were
8 engrafted into the right hind-leg of mice under desflurane anesthesia (8-10% desflurane, 30% oxygen/air) (Schubert et al.
9 2017).
10

11
12 *Biodistribution.* Investigation of biodistribution of ^{64}Cu -radiolabeled peptide conjugates followed a protocol published
13 elsewhere with some modifications (Bergmann et al. 2013). In brief, 8 rats received injections into a lateral tail vein under
14 anesthesia (inhalation of 9-10% desflurane (Suprane, Baxter, Germany) in 30% oxygen/air (gas flow 0.5 L/min)). The
15 injection volume of either [^{64}Cu]Cu-1 or [^{64}Cu]Cu-2 (0.5 MBq/animal; radiochemical purity of >98%; specific activity
16 0.2 to 1 MBq/ μg , molar activity 0.5 to 2.3 GBq/ μmol), dissolved in electrolyte solution E-153 (Serumwerk Bernburg,
17 Germany)), pH 7.2, was 0.5 mL. Biodistribution was determined in groups of four rats (per time point) sacrificed by heart
18 puncture under anesthesia at 5 min and 60 min post injection (p.i.). Organs and tissues of interest (blood, brain, brown
19 adipose tissue (BAT), white adipose tissue (WAT), thyroid gland, thymus, harderian glands (Harderian.gl.), heart, lungs,
20 muscle, pancreas, skin, spleen, femur, testes, adrenals, kidneys, liver, intestine and stomach) were rapidly excised,
21 weighed, and the activity determined in a Wallac WIZARD Automatic Gamma Counter and a dose calibrator (dose
22 calibrator ISOMED 2000, MED Nuklear-Medizintechnik Dresden GmbH, Dresden, Germany), respectively. The activity
23 of ^{64}Cu in the tissue samples was decay-corrected and calibrated by comparing the counts in tissue with the counts in
24 aliquots of injected radiotracer that have been measured both in the gamma counter and the dose calibrator and at the
25 same time. The activity concentration in organs and tissues was calculated as standardized uptake value ($\text{SUV} = (\text{activity}$
26 $\text{in the organ} / \text{weight of the organ}) / (\text{injected activity} / \text{animal weight})$). The accumulated activity %ID was calculated for
27 all fully extractable organs. The intestine and stomach were measured with content (w.c.) and urine activity was calculated
28 as the difference between the activity recovery and the injected activity.
29
30
31
32
33
34
35
36
37
38

39 For investigation of blood clearance and metabolic stability, blood samples were taken at 1, 3, 5, 10, 20, 30 und 60 min
40 p.i. and measured in a gamma counter. For in vivo stability, the percentage of intact radiolabeled compound was
41 determined via HPLC, 0, 1, 3, 10, 20 and 30 min after injection of [^{64}Cu]Cu-1 or [^{64}Cu]Cu-2 (Fig S1).
42
43

44 *Small animal PET.* ^{64}Cu -labeled GE11 conjugates **1** and **2** (10 to 20 MBq) of high molar activity (400 to 700 GBq/ μmol)
45 and ([^{64}Cu]Cu-NOTA)₃-C225 (20 MBq, molar activity 50 to 100 GBq/ μmol) were injected into the tail vein of FaDu
46 tumor bearing mice kept under general desflurane anesthesia. The PET studies were performed over a period of 1 h
47 ([^{64}Cu]Cu-1 or [^{64}Cu]Cu-2) and 36 h ([^{64}Cu]Cu-NOTA)₃-C225) with a small animal PET scanner (micro PET® P4,
48 Siemens medical solutions, Knoxville, TN, USA). The emission data were reconstructed, random coincidences subtracted
49 and the detector efficiencies were normalized using the producer's software. The ROVER software (ABX GmbH,
50 Radeberg, Germany) was used for data evaluation. The injected dose was calculated from the activity difference of the
51 syringe before and after injection having been measured with a cross calibrated dose calibrator. The data were used to
52 calculate SUV ($\text{SUV for PET: averaged activity concentration in a region of interest (ROI)} / \text{injected activity} \times \text{animal}$
53 weight).
54
55
56
57
58
59
60
61
62
63
64
65

Of note, the approved animal experiments (reference number 24-9168.21-4/2004-1) a priori were planned as an orientation survey (pilot study) to at least prove the harmlessness of a novel (radioligand) potential of radiotracers in the interest of (radio)pharmaceutical drug safety.

Results

Preparation, radiochemical characterization and stability of the conjugates

The GE11 peptide was obtained commercially with an additional β -alanine at the N-terminus, in order to allow coupling of the chelating agent *p*-SCN-Bn-NOTA. The purity of the peptide conjugate was higher than 99% verified with analytical HPLC, and characterized by MALDI-TOF/TOF mass spectrometry. However, the EG-linkerfree conjugated NOTA-derivative was not soluble in aqueous buffer, only with addition of an organic solvent like ethanol (> 20%). Therefore, a hydrophilic EG-based linker molecule was introduced between the N-terminus of the peptide and the chelator (Fig. 1A,B).

For coupling with the GE11 peptide at the N-terminus the linker precursor contained a Fmoc protected amino group and a reactive free carboxylic group. The *p*-SCN-Bn-NOTA was coupled with the deprotected linker-amino group. The in vitro stability of the ^{64}Cu -labeled peptide conjugate **1** was investigated in 0.2 M MES buffer (pH 6.2) and in cell medium DMEM + 10% FCS (w/ and w/o A431 cells) (Table 1). Further, the stability in human blood serum and binding of human serum components in vitro was determined. Whereas the stability in buffer and cell medium was excellent high after 24 h with more than 95% for the radiolabeled peptide **1**, the stability decreased in human blood serum within 24 h to only about 50% of parental compound. MALDI-TOF mass analysis was used for the investigation of degradation products upon incubation with human serum. With this method, the parenteral compound and two metabolites were detected, with masses that correspond to following cleavage products: 2370.2 [M+H]⁺ (Cu-**1**), 1899.7 [M+H]⁺ (Cu-NOTA-linker- β -Ala-Tyr-His-Trp-Tyr-Gly-Tyr-Thr-Pro), 1542.5 [M+H]⁺ (Cu-NOTA-linker- β -Ala-Tyr-His-Trp-Tyr-Gly).

The mass data might indicate an exopeptidase-mediated cleavage with begin at the free C-terminus of the peptide. One conventional method to prevent proteolytic cleavage is to protect the C-terminal carboxyl group by amidation (Di 2015). Thus, β -Ala-GE11-NH₂ was conjugated to the linker and the NOTA chelator similar to **1** to obtain **2** (Fig. 1A,B). The stability of [^{64}Cu]Cu-**2** in human blood serum was improved resulting in $\geq 70\%$ unmetabolized product after 24 h.

The octanol/buffer partition coefficient (Log*D*) determination with the shake-flask method yielded values -3.81 and -3.32 for the ^{64}Cu -labeled conjugate **1** and **2**, respectively (Table 1).

In vitro cell assays

The NOTA-conjugated peptides **1** and **2** were labeled with ^{64}Cu with a radiochemical purity > 95% (as determined radio-HPLC). For the in vitro assays, the molar activities of [^{64}Cu]Cu-**1** and [^{64}Cu]Cu-**2** ranged between 5 and 25 GBq/ μmol at the end of radiolabeling procedure, whereas for the in vivo studies [^{64}Cu]Cu-**1** and [^{64}Cu]Cu-**2** were obtained with higher molar activities up to 700 GBq/ μmol . The radiometric HPLC analysis of [^{64}Cu]Cu-**1** and [^{64}Cu]Cu-**2** is presented in Fig. 2. For both peptides a single peak (with a very weak shoulder in Fig. 2A) was observed at a retention time of 11.5 and 11.8 min, respectively, whereas the peak for free [^{64}Cu]CuCl₂ already appeared at 2.7 min.




Fig. 2 Analytical radio-HPLC chromatogram of (A) $[^{64}\text{Cu}]\text{Cu-1}$ ($t_R = 11.5$ min) and (B) $[^{64}\text{Cu}]\text{Cu-2}$ ($t_R = 11.8$ min).

Table 1 Log*D* of the radiolabeled conjugates as well as stability in 0.2 M MES buffer (pH 6.2), in human blood serum, and in cell medium w/ and w/o A431

	Time	$[^{64}\text{Cu}]\text{Cu-1}$	$[^{64}\text{Cu}]\text{Cu-2}$
Log <i>D</i>		-3.81 ± 0.06	-3.32 ± 0.03
0.2 MES buffer (pH 6.2)	2 h	$\geq 99\%$	$\geq 96\%$
	24 h	$\geq 97\%$	$\geq 97\%$
Human blood serum	2 h	$\geq 93\%$	$\geq 98\%$
	24 h	$\geq 50\%$	$\geq 70\%$
DMEM w/ A431, w/ 10% FCS	1 h	$\geq 94\%$	$\geq 95\%$
	24 h	$\geq 94\%$	$\geq 92\%$
DMEM w/o A431, w/ 10% FCS	1 h	$\geq 98\%$	$\geq 95\%$
	24 h	$\geq 98\%$	$\geq 95\%$

Tests were performed at 37 °C, at least three independent experiments

Cell assays

The immunologic detection of protein levels for the EGFR in A431, FaDu and MDA-MB-435s cells is demonstrated in Fig. 3 showing the abundance of endogenously expressed receptor protein: high for A431, moderate for FaDu and no detectable EGFR protein for MDA-MB-435s.




Fig. 3 Detection of endogenous EGFR expression of A431, FaDu and MDA-MB-435s (negative control) cells relative to β -actin expression by Western blotting

The influence of β -Ala-GE11 compared to C225 on the viability of A431, FaDu and MDA-MB-435s cells was investigated by applying the MTS test. Treatment with the peptide conjugates even at concentrations of 130 μM did not notably influence the viability of the three cell lines after 24 h (Fig. 4 A). In contrast, treatment with only 330 nM C225

tended to decrease the viability of FaDu and A431 cells after 24 h whereas on MDA-MB-435s cells the viability did not change (Fig. 4 B).




Fig. 4 Effects of (A) β -Ala-GE11 and (B) C225 treatment on the viability of A431 (solid black line, black triangles), FaDu (solid gray line, empty triangles) and MDA-MB435s cells (dashed black line, asterisks) after 24h. Results are expressed as percentages of the untreated medium control value. Each data point represents the mean from two to four experiments \pm SEM

Saturation binding assays were performed to determine the binding affinity of ^{64}Cu -labeled peptide conjugates **1** and **2**. Initially, the experiments were conducted on cell homogenates with a cell harvester that uses a filter to trap the cell membrane. However, ^{64}Cu -**1** or **2** resulted not in any specific binding for A431, FaDu as well as for MDA-MB-453s cells. Instead, saturation assays with established standard conjugate (^{64}Cu)-C225 showed moderate to high affinity on A431 and FaDu cell homogenate: K_d 8.5 ± 3.6 nM and 0.6 ± 0.1 nM, respectively. The B_{max} was 63.8 ± 9.4 pmol/mg and 4.8 ± 0.5 pmol/mg protein for A431 and FaDu homogenate, respectively (Fig. 5A,B). For MDA-MB-453s cells hardly any specific binding could be determined with (^{64}Cu)-C225 (Fig. 5C). At 4°C the K_d value for A431 was higher (18 ± 3), but B_{max} did not change; and for FaDu homogenate similar binding data were obtained.





Fig. 5 Binding curves of (^{64}Cu)-NOTA₃-C225 from saturation assays on (A) A431, (B) FaDu and (C) MDA-MB-453s (negative control) cell homogenate at 37°C . The curves comprise data of one representative assay from a total of four independent assays. (Empty triangle, black line: total binding; asterisks, dotted line: nonspecific binding; black triangle, gray line: specific binding)

1 Closer to natural conditions is the incubation of the radiolabeled peptides on intact cells direct in the growing wells.
 2 Again, saturation assays using [⁶⁴Cu]Cu-1 or 2 on intact cell condition did not show analyzable specific binding neither
 3 for A431 nor for FaDu and also not for the negative control cell line MDA-MB-453s (Fig. 6). For ([⁶⁴Cu]Cu-NOTA)₃-
 4 C225 the K_d-values were 8.3 ± 1.5 nM (A431) and 0.9 ± 0.2 (FaDu) and the B_{max} was 17.7 ± 1.5 (A431) and 1.3 ± 0.1
 5 pmol/mg protein (FaDu) at 4 °C. At 37 °C, the values for A431 cells differ clearly from those measured at 4 °C with a K_d
 6 37.1 ± 8.6 nM and B_{max} 56.6 ± 9.6 pmol/mg protein, whereas the values for FaDu cells were almost similar with a K_d 0.7
 7 ± 0.1 nM and B_{max} 2.7 ± 0.1 pmol/mg protein.
 8



9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37 **Fig. 6** Binding curves of [⁶⁴Cu]Cu-1 (upper row) and [⁶⁴Cu]Cu-2 (lower row) from saturation assays on (A,D) A431,
 38 (B,E) FaDu and (C,F) MDA-MB-453s on intact cells at 37°C. The curves comprise data of two independent assays.
 39 (Empty triangle, black line: total binding; asterisks, dotted line: nonspecific binding; black triangle, gray line: specific
 40 binding)

41
42 In the competition assay on A431 cells, increasing C225 concentration caused a progressive displacement of the
 43 ([⁶⁴Cu]Cu-NOTA)₃-C225 from its EGFR binding sites (Fig. 7A). The unlabeled antibody was able to displace ([⁶⁴Cu]Cu-
 44 NOTA)₃-C225 completely upon an 100-fold excess. The affinity at 4 °C and 37 °C was almost similar with K_i-values for
 45 C225 of 2.1 and 1.6 nM for 4 °C and 37 °C, respectively. ([⁶⁴Cu]Cu-NOTA)₃-C225 binding was also reduced with
 46 increasing EGF concentration (Fig. 7B). However, EGF could not completely displace ([⁶⁴Cu]Cu-NOTA)₃-C225 from
 47 the EGFR. The rate of displacement and EGF-binding affinity was temperature-dependent. At 37 °C, ([⁶⁴Cu]Cu-NOTA)₃-
 48 C225 could be displaced more efficiently and the affinity of EGF was higher (K_i 16 nM) than at 4 °C (K_i 58 nM). In
 49 contrast, β-Ala-GE11 had no effect on binding of ([⁶⁴Cu]Cu-NOTA)₃-C225 even at an excess of 1 × 10⁶ with respect to
 50 the applied molar concentration (Fig. 7C).
 51
52
53
54
55
56
57
58
59
60
61
62
63
64
65





Fig. 7 Displacement assays with (A) C225, (B) EGF and (C) β -Ala-GE11 versus $[\text{}^{64}\text{Cu}]\text{Cu-NOTA}_3\text{-C225}$ using vital A431 cells at 4 °C (white triangles) and 37 °C (black triangles). The curves illustrate data of one representative assay. Data points are the mean of three samples \pm SD

In a second competition study, EGF should displace GE11 (without modification). On serum-starved A431 cells, EGF induced the phosphorylation of the EGFR at Y1173-position (tyr), one of the three major phosphorylation sites at the regulatory domain (Fan et al. 2005); this phosphorylation could in turn be reduced by C225 (Fig. 8). No change in the phosphorylation state could be observed by treating A431 cells with GE11 or C225 alone. However, it was intended to show whether GE11 could either block or stimulate the activation of pEGFR, GE11 could not inhibit the phosphorylation, even not at 10000-fold excess over EGF.



* = Vehicle control (PBS + 5% DMSO)

Fig. 8 Immunologic detection of EGFR (Y1173) phosphorylation levels, EGFR and β -actin upon treatment with EGF in combination with C225 or GE11. Vehicle control was PBS + 5% DMSO. Western blot analysis (lower part) was performed for phosphorylated EGFR (pEGFR, Y1173), total EGFR, and β -actin by incubation with respective primary antibodies followed by incubation with HRP-coupled secondary antibodies and chemiluminescence detection. The different intensity of β -actin and EGFR bands occurred since the blot of the last 4 lanes on the right side was obtained from a separated immunoblotting assay. The data represent only qualitative estimation. Similar results were obtained in three independent experiments

In contrast to C225, the phosphorylation degree seems to be increased when EGF and GE11 were added in combination to A431 cells. However, this increase also appeared for the GE11 vehicle control (PBS + 5% DMSO).

In vivo studies

Biodistribution studies of the radiolabeled peptides $[\text{}^{64}\text{Cu}]\text{Cu-1}$ and $[\text{}^{64}\text{Cu}]\text{Cu-2}$ were carried out in healthy rats; the organs were measured 5 and 60 min after injection of the tracer. Notably uptake was determined only in the excretory organs; in the other organs investigated, the SUVs were lower or about 1 (Fig. S2, Table S1). Fig. 9 shows levels of total uptake in kidney, liver, intestine, stomach and urine. The uptake of $[\text{}^{64}\text{Cu}]\text{Cu-2}$ was higher than of $[\text{}^{64}\text{Cu}]\text{Cu-1}$ in intestine, and in liver only 5 min p.i. The levels of both radioconjugates decreased slightly in kidney 60 min after injection. The $[\text{}^{64}\text{Cu}]\text{Cu-}$

1 and $[^{64}\text{Cu}]\text{Cu-2}$ levels in the liver was low after 60 min. In intestine and urine, the uptake of both radioconjugates increased strong 60 min p.i. (Fig. 9).




Fig. 9 Biodistribution of $[^{64}\text{Cu}]\text{Cu-1}$ (white columns), $[^{64}\text{Cu}]\text{Cu-2}$ (gray columns) in the excretory organs of healthy rats in % ID (n = 8), 5 min and 60 min p.i.; *intestine and urine data are presented in % ID

The blood clearance was investigated and showed an elimination half-life of 3 min for $[^{64}\text{Cu}]\text{Cu-1}$ and 3.3 min for $[^{64}\text{Cu}]\text{Cu-2}$ (Fig. 10). The stability of $[^{64}\text{Cu}]\text{Cu-1}$ and $[^{64}\text{Cu}]\text{Cu-2}$ determined from in vivo blood samples (Fig. S1) resulted in only around 60% of both original tracers, 3 min p.i. After 10 min only about 10% of both conjugates was left (Fig. 11).




Fig. 10 Blood clearance of $[^{64}\text{Cu}]\text{Cu-1}$ (black triangles) and $[^{64}\text{Cu}]\text{Cu-2}$ (empty triangles) from venous blood of Wistar rats, (uncorrected for metabolite formation)




Fig. 11 Stability of $[^{64}\text{Cu}]\text{Cu-1}$ (white columns) and $[^{64}\text{Cu}]\text{Cu-2}$ (gray columns) in blood plasma of healthy rats.

PET images (Fig. 12A,B) showed a high uptake of $[^{64}\text{Cu}]\text{Cu-1}$ and $[^{64}\text{Cu}]\text{Cu-2}$ in kidney and bladder 5 min p.i. Towards image acquisition times of 20 min or 60 min the uptake in the intestines increased. Concerning the uptake in the tumor,





Fig. 12 PET images of (A) $[^{64}\text{Cu}]\text{Cu-1}$ and (B) $[^{64}\text{Cu}]\text{Cu-2}$ from FaDu tumor bearing mice, 5 min (left), 20 min (middle) and 60 min (right) p.i.; (C) PET images of $([^{64}\text{Cu}]\text{Cu-NOTA})_3\text{-C225}$ from FaDu tumor bearing mice, 2 h (left) and 23 h (right) p.i.; the arrows indicate the position of EGFR-FaDu-tumor; b: bladder, i: intestine, k: kidney, l: liver

1 some accumulation of [^{64}Cu]Cu-1 could be observed 5 min p.i., thereafter the activity decreased (Fig. 12A). For [^{64}Cu]Cu-
2 2, a rather blurred low tumor accumulation was observed (Fig. 12B) 5 and 20 min p.i. In comparison, PET images after
3 ([^{64}Cu]Cu-NOTA₃)-C225 injection revealed clear tumor uptake 2 h p.i. that increased 23 h i.p., however a high liver
4 uptake can be observed. The PET images from [^{64}Cu]Cu-1, [^{64}Cu]Cu-2 and ([^{64}Cu]Cu-NOTA₃)-C225 were not
5 standardized to each other as the principle purpose was to visualize the tumor site only qualitatively.
6
7
8

9 The low appearance of radioactive substance in the tumor of the two labeled conjugates can be compared by SUVs
10 directly, confirming a lower tumor accumulation with [^{64}Cu]Cu-2 for the complete PET recording (Fig. 13A). For the two
11 labeled peptides the tumor-to-muscle ratio increased for [^{64}Cu]Cu-1 until about 60 min and for [^{64}Cu]Cu-2 until about 45
12 min (Fig. 13B).
13
14
15



31 **Fig. 13** (A) SUVs and (B) tumor-to-muscle ratios of [^{64}Cu]Cu-1 (black triangles) and [^{64}Cu]Cu-2 (empty triangles)
32
33

34 The highest tumor-to-muscle ratio was determined for [^{64}Cu]Cu-1 with a value of 3.75 at 60 min p.i. The highest values
35 for [^{64}Cu]Cu-2 was about 2.5 after 45 min (Fig. 13B). Even if the appearance of [^{64}Cu]Cu-2 in the tumor was low, the
36 tumor-to-muscle ratios were slightly higher until 40 min p.i. compared to [^{64}Cu]Cu-1.
37
38
39

40 Discussion

41 Since the EGFR is overexpressed in a wide range of epithelial carcinoma it has long been pursued for molecular cancer
42 therapy, whereby monoclonal antibodies such as C225 have been successfully applied (Sihver et al. 2014). However, for
43 PET imaging, a major drawback of monoclonal antibodies is their large size resulting in slow tumor accumulation and
44 undesired enrichment in the liver. Hence, smaller radioligands, such as targeted peptides, possess several attractive
45 characteristics (Signore et al. 2001; Reubi and Maecke 2008). The dodecapeptide GE11 was reported to bind specifically
46 at the EGFR and furthermore exhibited promising results when conjugated with large chemical groups (Li et al. 2005).
47 Thus, it is reasonable to assume that conjugating β -Ala-GE11 with an EG-based linker and ^{64}Cu -NOTA will hardly affect
48 the radiopharmacological properties. Nonetheless, the pharmacological characteristics, regarding binding affinity,
49 selectivity, metabolism and biological activity had to be validated in vitro using EGFR-rich and EGFR-poor cell
50 preparations. Furthermore, preliminary in vivo studies should show a trend as to whether one of the radioconjugates might
51 be appropriate for future applications.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Peptides

1 β -Ala-GE11 and β -Ala-GE11-NH₂ were conjugated successfully and in sufficient yields with the EG-based linker and
2 the chelator *p*-SCN-Bn-NOTA. The bifunctional linker has also been linked directly to the N-terminal amino group of β -
3 Ala in β -Ala-GE11 but has not been further characterized biologically since it was hardly water soluble.

4
5 The radiolabeled conjugates showed very weak shoulders in the HPLC results that could be justified by the phenomenon
6 of an isomer formation after complexation with ⁶⁴Cu after labeling (Schlesinger et al. 2011). Furthermore, they showed
7 high stability in buffer and cell medium and in human serum for at least 2 h. It is known that C-terminal amides might
8 prevent degradation by endopeptidases (Brinckerhoff et al. 1999; Landon et al. 2004), thereby increasing the in vivo
9 stability; thus, after 24 h the serum stability of the amid conjugate [⁶⁴Cu]Cu-2 was found to be higher (70%) than for
10 [⁶⁴Cu]Cu-1 (50%). Since the aim was tumor imaging as a diagnostic method high peptide stability is required. The analysis
11 of [⁶⁴Cu]Cu-1 in MALDI-TOF resulted, presumably in two main metabolites and the original compound, whereby the
12 cleavage was assumed to be within the peptide. The induction of the fragmentation was assumed to be caused primarily
13 by peptidases in the serum (Stewart and Gilvarg 1999; Moughan and Stevens 2013).

In vitro characterization

14
15
16
17
18
19
20
21 The cell viability tests with the β -Ala-GE11 peptide, up to a concentration of 130 μ M (210 μ g/ml β -Ala-GE11) revealed
22 no change in viability using the applied cancer cells, whereas Li *et al.* (2005) showed stimulated growth of around 10%
23 for EGFR expressing human hepatoma cells after GE11 treatment (1 μ g/mL). Their data suggest that GE11 acts as partial
24 EGFR agonist, since human EGF also stimulated the growth by about 50%. In another study, treatment with
25 phthalocyanine-GE11 conjugates on A431 (and other cell lines) showed somewhat decreased cell viability after 24 h,
26 however with a fluorescence-based assay (cell titer blue) (Ongarora et al. 2012). Furthermore, PEG-liposome-GE11
27 conjugates did not exhibit any change in cell viability after 48 h on EGFR expressing lung carcinoma cells (Cheng et
28 al.2014). Obviously from these studies, conjugates of GE11 show no or only minor influence concerning cell viability.
29 Further evidence that GE11 does not exert physiological effects could be proved with the attempted immunologic
30 detection of EGFR (Y1173) phosphorylation upon treatment with GE11 (up to 1 mg/mL). It neither stimulated EGFR
31 phosphorylation nor decreased the phosphorylation degree after pre-stimulation with EGF. The enhanced phosphorylation
32 level in the Western blot, after GE11 addition (Fig. 8, lane 5 to 8) might appear due to the vehicle DMSO (Rubin and
33 Earp 1983; Luetkeke et al. 1994).

34
35
36
37
38
39
40
41 Saturation binding assays with ([⁶⁴Cu]Cu-NOTA₃)-C225 resulted in high specific binding and good affinities at A431 and
42 FaDu cells, whereas no binding was observed using the non-EGFR expressing MDA-MB-435s cells. For C225 high
43 affinities have been previously reported (0.1-0.2 nM) (Goldstein et al. 1995). The affinity of the radiolabeled antibody
44 with K_d-values in the low nanomolar range, is definitely sufficiently high. With regard to the determined B_{max}-values, it
45 was verified that A431 cells have a several fold higher EGFR density then FaDu cells. On living cells, the affinity is
46 temperature-dependent, thus internalization processes should be considered (Fan et al. 1994; Prewett et al. 1996). Such
47 processes are usually inhibited at 4 °C and will not appear in cell homogenates.

48
49
50
51
52
53 Saturation assays with [⁶⁴Cu]Cu-1 and potentially stabilized [⁶⁴Cu]Cu-2, resulted in linear binding isotherms, i.e. not
54 hyperbolic. The level of total and nonspecific binding was similarly high, and no bound part could be measured, neither
55 on intact cells nor in homogenate, at either incubation temperatures, and w/ or w/o protein serum. These data show that
56 the radioconjugates were not able to target the EGFR under in vitro conditions. Thus, the outcome of the binding studies
57 with [⁶⁴Cu]Cu-1 and [⁶⁴Cu]Cu-2 differs strongly from the results of Li et al. (2005) and Song *et al.* (2008) who reported
58 to have observed a high EGFR affinity and specificity of GE11-based conjugates. These contradictory results might
59
60
61
62
63
64
65

1 suggest that conjugation with the linker and bifunctional chelator (BFC) *p*-SCN-Bn-NOTA, alters the chemical
2 characteristics of the GE11-peptide (*e.g.* charge, size and polarity) leading to a loss in EGFR affinity and specificity.
3 Therefore, the binding ability of GE11 alone was determined. Since EGF and GE11 share the same EGFR binding site as
4 reported by Ongarora *et al.* (2012) GE11 should have the potency to compete with bound EGF from the receptor. Indeed,
5 effective GE11-blocking was shown with EGF also being able to displace GE11 from the EGFR (Li *et al.* 2005).
6 Additionally, C225 can block EGF-binding and EGF-induced EGFR autophosphorylation (Fan *et al.* 1994; Ferraro *et al.*
7 2013). Though, the EGFR-targeting ability of GE11 was determined by displacement assays with ([⁶⁴Cu]Cu-NOTA₃)-
8 C225. Once more, GE11 was not able to block or displace the binding ligand from the EGFR. In conclusion, the inability
9 of [⁶⁴Cu]Cu-1 and [⁶⁴Cu]Cu-2 to bind at the receptor is not due to chemical alterations by adding of linker and BFC, but
10 rather a general incapability of GE11 alone.
11
12
13

14 Interestingly, some studies also show a poor to negligible targeting-ability of GE11. For example, Abourbeh *et al.* (2012)
15 quantified the binding parameter of [¹²⁴I]-GE11 and [¹²⁵I]-EGF on A431 cells. Whereas [¹²⁵I]-EGF exposed a similar
16 binding affinity as described in literature ($K_d \sim$ low nanomolar range) (Björkelund *et al.* 2011) [¹²⁴I]-GE11 showed high
17 nonspecific binding (80-90%). In an [¹²⁵I]-EGF displacement assay, GE11 (up to 1 mM) was not able to dislocate EGF
18 from the EGFR. But when GE11 was tethered with PEG-PEI the binding affinity to the EGFR was increased and with
19 polyinosine/cytosine complexation the targeting-potency was enhanced (Abourbeh *et al.* 2012). Ongarora *et al.* (2012)
20 synthesized phthalocyanine-GE11 conjugates for potential use in photodynamic therapy of colorectal cancer. Using
21 docking studies, they were able to modulate the GE11-EGFR interactions and derived two important results: (I) GE11
22 interacts over hydrogen-bonding interactions of the amino acids residues Y2 and I13 with the EGF-binding pocket. (II)
23 The peptide did not offer an overall secondary structure. The docking energy of the phthalocyanine-GE11 conjugates was
24 lower than for GE11 alone due to additional interactions of phthalocyanine with the EGFR. Thus, binding affinities could
25 be confirmed by surface plasmon resonance measurements. However, despite the promising results it was not possible to
26 detect binding of the conjugates on living cells (*e.g.* A431). This, together with the high hydrophobic character of GE11,
27 led to the suggestion that the peptide has a strong tendency for aggregation preventing the EGFR-targeting ability
28 (Ongarora *et al.* 2012). Results from a study with a Cy-dye and PEG based linked GE11 represented a measurable but
29 low affinity (μ M range), in glioblastoma cells (Agnes *et al.* 2012). A recent study with ^{99m}Tc labeled HYNIC-GE11
30 revealed an affinity of 73 nM in ovarian tumor cells (Rahmanian *et al.* 2017). Presumably, they measured the cell uptake
31 favored by the linkers. When comparing studies with synthesized GE11-based conjugates, it becomes evident that the
32 conjugates that successfully targeted the EGFR were tethered to PEI or PEG (Li *et al.* 2005; Klutz *et al.* 2011a, b;
33 Abourbeh *et al.* 2012; Mickler *et al.* 2012), or to cationic dendrimers (Grünwald *et al.* 2013). All of these components are
34 highly hydrophilic suggesting aggregate formation.
35
36
37
38
39
40
41
42
43
44
45
46

47 ***In vivo experiments***

48
49 Since, in recent studies, the affinity and specificity of ¹²⁵I-labeled GE11 has been described (Li *et al.* 2005), even if in the
50 present study these properties could not be confirmed, but a good *in vitro* stability could be measured, a pilot small animal
51 study should provide conclusive radiopharmacological information. Notably, the *in vivo* experiments were performed in
52 parallel to the *in vitro* studies once the conjugates were labeled successfully. The amide group at the C-terminus of
53 [⁶⁴Cu]Cu-2 was introduced to stabilize the peptide against proteolytic degradation and for slower clearance. Such
54 arrangement implicated higher uptake in liver and intestine. However, other biodistribution studies have been done in
55 mice bearing EGFR expressing tumor xenografts. For example, in the study of Li *et al.* (2005) a tumor uptake of 6 %ID/g
56 for ¹²⁵I-labeled GE11 at 30 min p.i. and still more than 3 %ID/g at 4 h p.i. was presented but they did not demonstrate the
57
58
59
60
61
62
63
64
65

peptide stability in blood and formation of metabolites (Li et al. 2005). In recent studies, the majority of GE11-peptide constructs investigated were tethered to other large molecules. This seems to be a reason for the slower uptake and clearance in body and tumor. Tethered peptides exhibited a higher uptake in the liver than in the kidney (Klutz et al. 2011a; Lee et al. 2015), whereby tumor accumulation was also higher than in the liver in the study of Klutz et al. (2011a). Likewise, some tumor uptake has been demonstrated after administration of EGFR targeted thiolated gelatin nanoparticles, however, the accumulation was very high in the liver, spleen and kidney (Xu et al. 2013). In vivo experiments with ^{99m}Tc-HYNIC-GE11 also showed low tumor uptake and similar tumor-to-muscle ratios as those of present study, but really high values in the kidney (Rahmanian et al. 2017). A GE11-liposome conjugate showed high uptake in liver and spleen up to 24 h p.i., however, some tumor accumulation has been detected after 12h p.i (Cheng et al. 2014). One phenomenon responsible for tumor uptake of large molecules, and perhaps large GE11 conjugate constructs is the enhanced permeability and retention (EPR) effect. Due to aberrant formations of tumor blood vessels and malfunctions of lymphatic vessels in tumor tissue the clearance of macromolecules and lipids is impaired, so that they remain in the tumor for a longer time (Fang et al. 2011). The non-tethered peptides in the present study showed low tumor uptake. Since the tracer molecules were rather small an EPR effect might be barely noticeable.

Summary and Conclusions

The β -Ala-GE11 peptide and its stabilized version β -Ala-GE11-NH₂, were successfully conjugated to an EG-based linker and with the BFC *p*-SCN-Bn-NOTA for further labeling with ⁶⁴Cu. The labeled conjugates were stable in buffer or cell medium. However, degradation in human serum after 24 h could be delayed to some extent by amidation of the free C-terminus. The binding affinity of the radiolabeled GE11-conjugates to EGFR failed to be determined in saturation and competition studies with cell lines of high EGFR expression. Biodistribution in rats as well as PET images from EGFR expressing tumor bearing mice showed notably accumulation of the labeled conjugates in the excretion organs. Whereas the uptake in the tumor itself was comparatively low, with a maximal tumor to muscle ratio of 3.75 for [⁶⁴Cu]Cu-1, 1 h p.i. Since for these types of small conjugates a strong tendency for aggregation is suggested, they do not represent suitable leads for novel EGFR-targeted imaging probes. Moreover, the rapid metabolism presumably also due to the linear nature of the peptides implies the need of peptide modification for stability improvement and/or better bioavailability for suitability as in vivo imaging and/or therapeutic agents. Efforts should focus on derivatives tethered with liposomes, PEGs and/or PEI, or, more promisingly, on other, e.g., antibody-based approaches.

Compliance with ethical standards

Ethical approval The animal experiments were performed in accordance to the guidelines of the German Regulations of Animal Welfare. The protocol was approved by the local Ethical Committee for Animal Experiments (reference number 24-9168.21-4/2004-1).

Conflict of interest The authors have no conflict of interest to declare.

References

- 1 Abourbeh G, Shir A, Mishani E, Ogris M, Rödl W, Wagner E, Levitzki A (2012) PolyIC GE11 polyplex inhibits EGFR-
2 overexpressing tumors. *IUBMB Life* 64: 324-330. doi: 10.1002/iub.1002
- 3 Agnes RS, Broome AM, Wang J, Verma A, Lavik K, Basilion JP (2012) An optical probe for noninvasive molecular
4 imaging of orthotopic brain tumors overexpressing epidermal growth factor receptor. *Mol Cancer Ther* 11: 2202-2211.
5 doi: 10.1158/1535-7163.MCT-12-0211
- 6 Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L (2002) Impact of epidermal growth
7 factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. *Cancer*
8 *Res* 62: 7350-7356
- 9 Banerjee SS, Aher N, Patil R, Khandare J (2012) Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and
10 Applications. *J Drug Deliv* 2012:103973. doi: 10.1155/2012/103973
- 11 Baumann M, Krause M (2004) Targeting the epidermal growth factor receptor in radiotherapy: radiobiological
12 mechanisms, preclinical and clinical results. *Radiother Oncol* 72: 257-266. doi: 10.1016/j.radonc.2004.07.007
- 13 Bergmann R, Ruffani A, Graham B, Spiccia L, Steinbach J, Pietzsch J, Stephan H (2013) Synthesis and
14 radiopharmacological evaluation of ⁶⁴Cu-labeled bombesin analogs featuring a bis(2-pyridylmethyl)-1,4,7-
15 triazacyclononane chelator. *Eur J Med Chem* 70: 434-446. doi: 10.1016/j.ejmech.2013.10.013
- 16 Björkelund H, Gedda L, Andersson K (2011) Comparing the epidermal growth factor interaction with four different cell
17 lines: intriguing effects imply strong dependency of cellular context. *PLoS One* 6: e16536. doi:
18 10.1371/journal.pone.0016536
- 19 Brinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH,
20 Slingluff CL Jr (1999) Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35)
21 peptide: implications for peptide vaccines. *Int J Cancer* 83: 326-334
- 22 Bröer S (2008) Amino acid transport across mammalian intestinal and renal epithelia. *Physiol Rev* 88: 249-286. doi:
23 10.1152/physrev.00018.2006
- 24 Chanda N, Zambre A, Shukla R, Mukharjee P, Mukhopadhyay D, Boote E, Kannan R, Katti KV (2010) Relative study
25 between anti-EGFR and GE11 peptide conjugated gold nanoparticles for in vivo targeting in pancreatic cancer.
26 <https://mospace.umsystem.edu/xmlui/handle/10355/9779>. Accessed 26 Octobre 2017
- 27 Chen K, Chen X (2010) Design and development of molecular imaging probes. *Curr Top Med Chem* 10:1227-1236
- 28 Cheng L, Huang FZ, Cheng LF, Zhu YQ, Hu Q, Li L, Wei L, Chen DW (2014) GE11-modified liposomes for non-small
29 cell lung cancer targeting: preparation, ex vitro and in vivo evaluation. *Int J Nanomedicine* 9: 921-935. doi:
30 10.2147/IJN.S53310
- 31 DeJesus OT (2012) Synthesis of [⁶⁴Cu]Cu-NOTA-Bn-GE11 for PET imaging of EGFR-rich tumors. *Curr Radiopharm*
32 5: 15-18
- 33 Di L (2015) Strategic approaches to optimizing peptide ADME properties. *AAPS J* 17: 134-143. doi: 10.1208/s12248-
34 014-9687-3
- 35 van Dijk LK, Boerman OC, Kaanders JH, Bussink J (2015) PET Imaging in Head and Neck Cancer Patients to Monitor
36 Treatment Response: A Future Role for EGFR-Targeted Imaging. *Clin Cancer Res* 21: 3602-3609. doi: 10.1158/1078-
37 0432.CCR-15-0348
- 38 Dissoki S, Hagooley A, Elmachily S, Mishani E (2011) Labeling approaches for the GE11 peptide, an epidermal growth
39 factor receptor biomarker. *J Labelled Compd Rad* 54: 693-701. doi: 10.1002/jlcr.1910
- 40 Fan YX, Wong L, Johnson GR (2005) EGFR kinase possesses a broad specificity for ErbB phosphorylation sites, and
41 ligand increases catalytic-centre activity without affecting substrate binding affinity. *Biochem J* 392: 417-423. doi:
42 10.1042/BJ20051122
- 43 Fan Z, Lu Y, Wu X, Mendelsohn J (1994) Antibody-induced epidermal growth factor receptor dimerization mediates
44 inhibition of autocrine proliferation of A431 squamous carcinoma cells. *J Biol Chem* 269: 27595-27602
- 45 Fang J, Nakamura H, Maeda H (2011) The EPR effect: Unique features of tumor blood vessels for drug delivery, factors
46 involved, and limitations and augmentation of the effect. *Adv Drug Deliv Rev* 63: 136-151. doi:
47 10.1016/j.addr.2010.04.009
- 48 Ferraro DA, Gaborit N, Maron R, Cohen-Dvashi H, Porat Z, Pareja F, Lavi S, Lindzen M, Ben-Chetrit N, Sela M, Yarden
49 Y (2013) Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. *Proc Natl Acad Sci*
50 *U S A* 110: 1815-1820. doi: 10.1073/pnas.1220763110

Genta I, Chiesa E, Colzani B, Modena T, Conti B, Dorati R (2018) GE11 Peptide as an Active Targeting Agent in Antitumor Therapy: A Minireview. *Pharmaceutics* 10, pii: E2. doi: 10.3390/pharmaceutics10010002

1 Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the
2 epidermal growth factor receptor in a human tumor xenograft model. *Clin Cancer Res* 1: 1311-1318.

3
4 Grünwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C,
5 Wagner E, Göke B, Holm PS, Ogris M, Spitzweg C (2013) EGFR-Targeted Adenovirus Dendrimer Coating for Improved
6 Systemic Delivery of the Theranostic NIS Gene. *Mol Ther Nucleic Acids* 2: e131. doi: 10.1038/mtna.2013.58.

7
8 Gutiérrez-García VM, Reyes-Rangel G, Muñoz-Muñiz O, Juaristi E (2001) Enantioselective synthesis of β -amino acids.
9 12. Experimental and theoretical study of the diastereoselectivity of alkylation of the dianion of N',N'-bis(α -phenylethyl)-
10 N-carbobenzyloxypropionamide. *J Braz Chem Soc* 12: 652-660

11 Haigler H, Ash JF, Singer SJ, Cohen S (1978) Visualization by fluorescence of the binding and internalization of
12 epidermal growth factor in human carcinoma cells A-431. *Proc Natl Acad Sci U S A* 75: 3317-3321

13
14 Heldt JM, Kerzendörfer O, Mamat C, Starke F, Pietzsch HJ, Steinbach J (2013) Synthesis of short and versatile
15 heterobifunctional linkers for conjugation of bioactive molecules with (radio-)labels. *Synlett* 24: 432-436. doi: 10.1055/s-
16 0032-1318198

17 Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ (2012) High management impact of Ga-68 DOTATATE
18 (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. *J Med Imaging Radiat Oncol*
19 56: 40-47. doi: 10.1111/j.1754-9485.2011.02327.x

20
21 Klutz K, Schaffert D, Willhauck MJ, Grünwald GK, Haase R, Wunderlich N, Zach C, Gildehaus FJ, Senekowitsch-
22 Schmidtke R, Göke B, Wagner E, Ogris M, Spitzweg C (2011a) Epidermal growth factor receptor-targeted (131)I-therapy
23 of liver cancer following systemic delivery of the sodium iodide symporter gene. *Mol Ther* 19: 676-685. doi:
24 10.1038/mt.2010.296

25
26 Klutz K, Willhauck MJ, Dohmen C, Wunderlich N, Knoop K, Zach C, Senekowitsch-Schmidtke R, Gildehaus FJ, Ziegler
27 S, Fürst S, Göke B, Wagner E, Ogris M, Spitzweg C (2011b) Image-guided tumor-selective radioiodine therapy of liver
28 cancer after systemic nonviral delivery of the sodium iodide symporter gene. *Hum Gene Ther* 22:1563-1574. doi:
29 10.1089/hum.2011.041

30 Koi L, Bergmann R, Bruchner K, Pietzsch J, Pietzsch HJ, Krause M, Steinbach J, Zips D, Baumann M (2014)
31 Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic
32 potential. *Radiother Oncol* 110: 362-369. doi: 10.1016/j.radonc.2013.12.001

33
34 Kondo M, Kimura M, Sato K, Horimoto H (1987) Synthesis and properties of [1,1'-bis(α -aminoisobutyric
35 acid)]gramicidin S and [1- α -aminoisobutyric acid]semigramicidin S. *Bull Chem Soc Jpn* 60: 1391-1397

36 Landon LA, Zou J, Deutscher SL (2004) Is phage display technology on target for developing peptide-based cancer drugs?
37 *Curr Drug Discov Technol* 1: 113-132

38
39 Lee D, Lee YM, Kim J, Lee MK, Kim WJ (2015) Enhanced tumor-targeted gene delivery by bioreducible
40 polyethylenimine tethering EGFR divalent ligands. *Biomater Sci* 3: 1096-1104. doi: 10.1039/c5bm00004a

41 Li Z, Zhao R, Wu X, Sun Y, Yao M, Li J, Xu Y, Gu J (2005) Identification and characterization of a novel peptide ligand
42 of epidermal growth factor receptor for targeted delivery of therapeutics. *FASEB J* 19: 1978-1985. doi: 10.1096/fj.05-
43 4058com

44
45 Lindenberg L, Adler S, Turkbey IB, Mertan F, Ton A, Do K, Kummur S, Gonzalez EM, Bhattacharyya S, Jacobs PM,
46 Choyke P (2017) Dosimetry and first human experience with 89Zr-panitumumab. *Am J Nucl Med Mol Imaging* 7: 195-
47 203

48 van Loon J, Even AJG, Aerts HJWL, Öllers M, Hoebbers F, van Elmpt W, Dubois L, Dingemans AC, Lalisang RI,
49 Kempers P, Brans B, Winnepenninckx V, Speel EJ, Thunnissen E, Smits KM, Boellaard R, Vugts DJ, De Ruyscher D,
50 Lambin P (2017) PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and
51 lung cancer. *Radiother Oncol* 122: 267-273. doi: 10.1016/j.radonc.2016.11.020

52
53 Luetteke NC, Phillips HK, Qiu TH, Copeland NG, Earp HS, Jenkins NA, Lee DC (1994) The mouse waved-2 phenotype
54 results from a point mutation in the EGF receptor tyrosine kinase. *Genes Dev* 8: 399-413

55
56 Martinez-Useros J, Garcia-Foncillas (2015) The challenge of blocking a wider family members of EGFR against head
57 and neck squamous cell carcinomas. *Oral Oncol* 51: 423-430. doi: 10.1016/j.oraloncology.2015.02.092

58
59 Master A, Malamas A, Solanki R, Clausen DM, Eiseman JL, Sen Gupta A (2013) A cell-targeted photodynamic
60 nanomedicine strategy for head and neck cancers. *Mol Pharm* 10: 1988-1997. doi: 10.1021/mp400007k

- Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. *Semin Oncol* 33: 369-385. doi: 10.1053/j.seminoncol.2006.04.003
- 1 Mickler FM, Möckl L, Ruthardt N, Ogris M, Wagner E, Bräuchle (2012) Tuning nanoparticle uptake: live-cell imaging
2 reveals two distinct endocytosis mechanisms mediated by natural and artificial EGFR targeting ligand. *C. Nano Lett* 12:
3 3417-23
- 4 Moughan PJ, Stevens BR (2013) Chapter 9; Digestion and absorption of protein. In: Stipanuk MH, Caudill MA (ed)
5 Biochemical, physiological, and molecular aspects of human nutrition, 3rd edn. Elsevier Saunders, St. Louis, pp 162-178
- 6 Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. *Eur J Cancer* 37: 9-15
- 7
8
9 Ongarora BG, Fontenot KR, Hu X, Sehgal I, Satyanarayana-Jois SD, Vicente MG (2012) Phthalocyanine-peptide
10 conjugates for epidermal growth factor receptor targeting. *J Med Chem* 55: 3725-3738. doi: 10.1021/jm201544y
- 11 Petrucci JR, Hansen SB, Abourbeh G, Yaqub M, Bahce I, Holden D, Huang Y, Nabulsi NB, Contessa JN, Mishani E,
12 Lammertsma AA, Morris ED (2017) A multi species evaluation of the radiation dosimetry of [¹¹C]erlotinib, the
13 radiolabeled analog of a clinically utilized tyrosine kinase inhibitor. *Nucl Med Biol* 47: 56-61. doi: 10.1016/j.nucmedbio.
14 2016.12.009
- 15 Prewett M, Rockwell P, Rockwell RF, Mendelsohn J, Scher HI, Goldstein NI (1996) The biologic effects of C225, a
16 chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. *J Immunother Emphasis Tumor Immunol* 19:
17 419-427
- 18
19 Rahmanian N, Hosseinimehr SJ, Khalaj A, Noaparast Z, Abedi SM, Sabzevari O (2017) ^{99m}Tc-radiolabeled GE11-
20 modified peptide for ovarian tumor targeting. *Daru* 25: 13. doi: 10.1186/s40199-017-0179-8
- 21 Ren H, Gao C, Zhou L, Liu M, Xie C, Lu W (2015) EGFR-targeted poly(ethylene glycol)-distearoylphosphatidyl
22 ethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation, characterization and in vitro evaluation.
23 *Drug Deliv* 22, 785-794. doi: 10.3109/10717544.2014.896057
- 24 Reubi JC, Maecke HR (2008) Peptide-based probes for cancer imaging. *J Nucl Med* 49: 1735-1738. doi:
25 10.2967/jnumed.108.053041
- 26
27 Rubin RA, Earp HS (1983) Dimethyl sulfoxide stimulates tyrosine residue phosphorylation of rat liver epidermal growth
28 factor receptor. *Science* 219: 60-63
- 29 Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors
30 in human malignancies. *Crit Rev Oncol Hematol* 19: 183-232
- 31
32 Schlesinger J, Rajander J, Ihalainen JA, Ramesh D, Eklund P, Fagerholm V, Nuutila P, Solin O (2011) Isomerism of
33 [⁶⁴Cu-NOTA-Bn]-labeled radiotracers: separation of two complex isomers and determination of their interconversion
34 energy barrier using ion pair chromatography. *Inorg Chem* 50: 4260-4271. doi: 10.1021/ic101775q
- 35
36 Schubert M, Bergmann R, Förster C, Sihver W, Vonhoff S, Klussmann S, Bethge L, Walther M, Schlesinger J, Pietzsch
37 J, Steinbach J, Pietzsch HJ (2017) Novel tumor pretargeting system based on complementary l-configured
38 oligonucleotides. *Bioconjug Chem* 28: 1176-1188. doi: 10.1021/acs.bioconjchem.7b00045
- 39 Schütze C, Dörfler A, Eicheler W, Zips D, Hering S, Solca F, Baumann M, Krause M (2007) Combination of
40 EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell
41 carcinoma. *Strahlenther Onkol* 183: 256-264. doi: 10.1007/s00066-007-1696-z
- 42
43 Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P, Mossetti C, Ardisson F, Lausi P, Scagliotti GV
44 (2004) Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-
45 small-cell lung cancer. *Ann Oncol* 15: 28-32
- 46
47 Signore A, Annovazzi A, Chianelli M, Corsetti F, Van de Wiele C, Watherhouse RN (2001) Peptide radiopharmaceuticals
48 for diagnosis and therapy. *Eur J Nucl Med* 28: 1555-1565. doi: 10.1007/s002590100583
- 49
50 Sihver W, Pietzsch J, Krause M, Baumann M, Steinbach J, Pietzsch HJ (2014) Radiolabeled Cetuximab Conjugates for
51 EGFR Targeted Cancer Diagnostics and Therapy. *Pharmaceuticals (Basel)* 7: 311-338. doi: 10.3390/ph7030311
- 52 Song S, Liu D, Peng J, Sun Y, Li Z, Gu JR, Xu Y (2008) Peptide ligand-mediated liposome distribution and targeting to
53 EGFR expressing tumor in vivo. *Int J Pharm* 363: 155-161. doi: 10.1016/j.ijpharm.2008.07.012
- 54
55 Stewart JD, Gilvarg C (1999) Determination of the activity of carboxypeptidase A in the blood of healthy human adults.
56 *Clin Chim Acta* 281: 19-28
- 57
58 Tang H, Chen X, Rui M, Sun W, Chen J, Peng J, Xu Y (2014) Effects of surface displayed targeting ligand GE11 on
59 liposome distribution and extravasation in tumor. *Mol Pharm* 11: 3242-3250. doi: 10.1021/mp5001718
- 60
61
62
63
64
65

Thieme S, Walther M, Pietzsch HJ, Henniger J, Preusche S, Mäding P, Steinbach J (2012) Module-assisted preparation of ⁶⁴Cu with high specific activity. *Appl Radiat Isot* 70: 602-608. doi: 10.1016/j.apradiso.2012.01.019

1 Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y (2002) Prognostic and predictive value of
2 epidermal growth factor receptor in recurrent breast cancer. *Clin Cancer Res* 8: 3454-3460

3
4 Wee P, Wang Z (2017) Epidermal growth factor receptor cell proliferation signaling pathways. *Cancers* 9: pii:E52. doi:
5 10.3390/cancers9050052

6 Xu J, Gattacceca F, Amiji M (2013) Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin
7 nanoparticles following systemic administration in pancreatic tumor-bearing mice *Mol Pharm* 10: 2031-2044. doi:
8 10.1021/mp400054e

9
10 Yoshimoto M, Kurihara H2, Fujii H (2015) Theragnostic imaging using radiolabeled antibodies and tyrosine kinase
11 inhibitors. *ScientificWorldJournal* 2015: 842101. doi: 10.1155/2015/842101

12 Yu HM, Chen JH, Lin KL, Lin WJ (2015) Synthesis of (68)Ga-labeled NOTA-RGD-GE11 heterodimeric peptide for
13 dual integrin and epidermal growth factor receptor-targeted tumor imaging. *J Labelled Compd Rad* 58: 299-303. doi:
14 10.1002/jlcr.3296

15
16 Zarschler K, Prapainop K, Mahon E, Rocks L, Bramini M, Kelly PM, Stephan H, Dawson KA (2014) Diagnostic
17 nanoparticle targeting of the EGF-receptor in complex biological conditions using single-domain antibodies. *Nanoscale*
18 6: 6046-6056. doi: 10.1039/c4nr00595c



[Click here to access/download](#)

Supplementary Material

Ms. No. AMAC-D-18-00181 Suppl. material.docx

